Skip to content
Open in App
Natera Inc logo

Natera Inc

web2

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecu...

Symbol · NTRA
Company profile

About

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Signatera submitted to Japan PMDA for bladder cancer companion diagnostic

KEY STEP

On August 5, 2026, Natera submitted Signatera to Japan's Pharmaceuticals and Medical Devices Agency for approval as a companion diagnostic in muscle invasive bladder cancer. The application is supported by the IMvigor011 Phase 3 study and follows Signatera's earlier Japanese approval in colorectal cancer.

Roadmap reference
People

Company team

RF

Roelof Frederik Botha

Lead Independent Director

Company leadership profile.

TJ

Thomas J. Lynch

Independent Director

Company leadership profile.

MR

Matthew Rabinowitz

Co-Founder & Executive Chairman

Company leadership profile.

SL

Steven Leonard Chapman

CEO & Director

Company leadership profile.

JS

Jonathan Sheena

Co-Founder & Director

Company leadership profile.

HR

Herman Rosenman

Independent Director

Company leadership profile.

GB

Gail B. Marcus

Independent Director

Company leadership profile.

RE

Rowan E. Chapman

Independent Director

Company leadership profile.

RD

Roy D. Baynes

Independent Director

Company leadership profile.

RE

Ruth Evelyn Williams-Brinkley

Independent Director

Company leadership profile.

EH

Eric H. Rubin

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Natera Inc.

Orbitrum research

Experts evaluating Natera Inc

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment